Simparica Trio, Zoetis’ once-a-month combo parasite chew and the top veterinarian-prescribed product in its U.S. category, is headed to South Korea.
Zoetis Korea CEO Park Seong Jun said the company will launch Simparica Trio in Korea on March 3, citing Kynetec’s PetTrak data tracking the veterinary channel in the United States.
For American pet owners, the pitch is straightforward: one chew combines sarolaner, moxidectin, and pyrantel to help prevent heartworm disease while treating or controlling fleas, ticks, roundworms, and hookworms.
The product was first approved by the U.S. FDA in 2020, and in 2025, the FDA cleared an additional label claim related to preventing flea tapeworm infections by killing the vector fleas.
Zoetis is also leaning on moxidectin at a time when researchers have flagged pockets of reduced susceptibility to some heartworm preventives, with studies suggesting moxidectin can perform better than other macrocyclic lactones against resistant strains in controlled settings.
On the U.S. label, Simparica Trio is indicated for dogs and puppies 8 weeks of age or older weighing at least 2.8 pounds, and it comes in six weight-based tablet sizes (from toy breeds up to 132 pounds).
A Zoetis Korea spokesperson said the company expects the product to be a convenient, vet-friendly option for Korean pet owners looking for all-in-one monthly protection.